Rigel Pharmaceuticals, Inc. (RIGL)

NMS – Real vaqt narxi. Valyuta: USD

41.89

-0.13 (-0.31%)

Bozor ochiq: Aug 12, 2026, 2:49 PM EDT

42.39

+0.37 (0.88%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

05.08.2026

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties.

05.08.2026

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

05.08.2026

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August.

04.08.2026

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $3.28 per share a year ago.

04.08.2026

Rigel Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded commercial portfolio with the in-license of VEPPANU™ (vepdegestrant), with U.S. commercial availability expected in mid-August Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026 Updated 2026 Outlook: Total revenues of approximately $285 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $265 million and contract revenues from collaborations of approximately $30 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Rigel Pharmaceuticals, Inc. (RIGL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Rigel Reports Second Quarter 2026 Financial Results

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Rigel Reports Second Quarter 2026 Financial Results

Search stocks

Rigel Pharmaceuticals, Inc. (RIGL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Rigel Reports Second Quarter 2026 Financial Results

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Rigel Reports Second Quarter 2026 Financial Results